Mundipharma said that it has entered into a partnership with Samsung Bioepis to commercialize Samsung Bioepis’ biosimilar candidates in Taiwan and Hong Kong.
|Samsung Bioepis headquarters in Songdo, Incheon.|
The partnership covers Samsung Bioepis’ biosimilar candidates in the field of immunology and oncology, including SB5 (adalimumab), SB4 (etanercept), SB3 (trastuzumab) and SB8 (bevacizumab).
Under the accord, Mundipharma will be the exclusive commercialization partner. At the same time, Samsung Bioepis will remain the marketing authorization holder (MAH) responsible for clinical development, regulatory registration, and manufacture of the biosimilars.
“This partnership brings together Samsung Bioepis’ proven biosimilar development platform with Mundipharma’s commercial acumen and market insight and ability to increase patient access to proven treatments,” Mundipharma CEO Raman Singh said. “This partnership will help to address the patient need in two important territories in Asia for immunology and oncology treatments.”
<© Korea Biomedical Review, All rights reserved.>